As most healthcare investors know, waiting for key clinical trial results can be a little stressful even at the best of times. However today’s encouraging news from LungLife AI (LLAI) removes much of this uncertainty.
The next-generation lung cancer diagnostics firm said that influential industry journal BMC Pulmonary Medicine had independently peer-reviewed its flagship CTC (circulating tumour cells) and AI enhanced LungLB blood test, concluding that the cutting edge diagnostic had “outperformed other commonly used evaluation tools, including the Mayo Clinic risk model and PET scan.”
It found that LungLB’s biomarker was the strongest predictor of cancer across the 151 person study, and had “demonstrated robust performance wrt smaller indeterminate lung nodules, early-stage cancer patients and people who had never smoked (but might have ‘passively’ contracted the disease)”.
To me, this is not only another marvellous endorsement of LungifeAI's medical science, but also significantly derisks the release of its own findings from a separate 425 patient pivotal validation study in the next 3-4 months. And it supports the test's clinical use in reducing treatment delays, where positive LungLB readings can often be available months ahead of formal lung cancer detection.
CEO Paul Pagano commented: "Having the results of our study peer-reviewed is not only an independent confirmation of the scientific validity of our approach, but is also an important part of our strategic effort to build evidence for efficacy and utility in our efforts to increase access of our testing to those who need it most."
"We were excited to see that the LungLB performance remained strong in people who never smoked, because evidence has shown that the incidence of lung cancer in never smokers is increasing, and it is important new technologies address this expanding group."
"Additionally, LungLB® was able to detect cancer in its earliest stages, which can be the most challenging to diagnose for doctors and most beneficial for patients."